Market Spotlight: Pancreatic Cancer
Market Spotlight: Pancreatic Cancer
$1,318.00
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the pancreatic cancer market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were 453,200 incident cases of pancreatic cancer worldwide, and expects that number to increase to 495,900 incident cases by 2026.
- The approved drugs in the pancreatic cancer space target microtubules (tubulin), DNA, DNA synthesis, topoisomerase I, dihydropyrimidine dehydrogenase, thymidylate synthase, and epidermal growth factor receptor. These drugs are commonly administered via the intravenous route, with a few select products being available in oral and intratumoral formulations.
- The majority of industry-sponsored drugs in active clinical development for pancreatic cancer are in Phase II. Therapies in development for pancreatic cancer focus on a wide variety of targets. The majority of pipeline drugs for pancreatic cancer are administered via the oral and intravenous routes.
- High-impact upcoming events for drugs in the pancreatic cancer space comprise topline Phase IIb and Phase III trial results, and expected patent expirations.
- The overall likelihood of approval of a Phase I pancreatic cancer asset is 2.2%, and the average probability a drug advances from Phase III is 13.0%. Drugs, on average, take 10.6 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been 48 licensing and asset acquisition deals involving pancreatic cancer drugs during 2014–19. The $1,770m exclusive clinical collaboration agreement signed in 2014 between Bristol-Myers Squibb and Five Prime Therapeutics to explore the combination of Opdivo with FPA008 in six tumor types including pancreatic cancer was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for pancreatic cancer have been in the early and mid-phases of development, with 93% of trials in Phase I–II, and only 7% in Phase III–IV.
- The US has a substantial lead in the number of pancreatic cancer clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the pancreatic cancer space is dominated by completed trials. Roche has the highest number of completed clinical trials for pancreatic cancer, with 93 trials.
- Roche leads industry sponsors with the highest number of clinical trials for pancreatic cancer, followed by Eli Lilly.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Subtypes
10 TREATMENT
10 Surgery
10 Ablation or embolization
11 Radiation therapy
11 Chemotherapy
11 Targeted therapy
12 Immunotherapy
12 Drugs used specifically for the treatment of PNETs
13 EPIDEMIOLOGY
16 MARKETED DRUGS
19 PIPELINE DRUGS
40 RECENT EVENTS AND ANALYST OPINION
40 Mavorixafor for Pancreatic Cancer (July 17, 2019)
40 Napabucasin for Pancreatic Cancer (July 1, 2019)
41 Abraxane for Pancreatic Cancer (June 2, 2019)
42 Lynparza for Pancreatic Cancer (June 2, 2019)
44 MVT-5873 for Pancreatic Cancer (May 8, 2019)
45 Sacituzumab Govitecan for Pancreatic Cancer (April 29, 2019)
46 RX-3117 for Pancreatic Cancer (April 16, 2019)
47 Abraxane for Pancreatic Cancer (March 12, 2019)
49 Abraxane for Pancreatic Cancer (February 27, 2019)
50 Lynparza for Pancreatic Cancer (February 26, 2019)
51 SM-88 for Pancreatic Cancer (January 18, 2019)
53 BL-8040 for Pancreatic Cancer (October 19, 2018)
55 AM0010 for Pancreatic Cancer (June 3, 2018)
58 KEY UPCOMING EVENTS
59 PROBABILITY OF SUCCESS
60 LICENSING AND ASSET ACQUISITION DEALS
60 Ono Licenses Rafael’s Novel Chemo-Sensitizing Agent For Asia
60 Mateon, Oncotelic Merge With Focus On Brain, Pancreatic Cancer Candidate
61 BioSense Picks Up Greater China Rights To Rexahn’s Cancer Candidate
62 PARENT PATENTS
64 REVENUE OPPORTUNITY
66 CLINICAL TRIAL LANDSCAPE
67 Sponsors by status
68 Sponsors by phase
69 Recent events
71 BIBLIOGRAPHY
71 Prescription information
73 APPENDIX
LIST OF FIGURES
15 Figure 1: Trends in incident cases of pancreatic cancer, 2017–26
19 Figure 2: Overview of pipeline drugs for pancreatic cancer in the US
19 Figure 3: Pipeline drugs for pancreatic cancer, by company
20 Figure 4: Pipeline drugs for pancreatic cancer, by drug type
20 Figure 5: Pipeline drugs for pancreatic cancer, by classification
44 Figure 6: Lynparza for Pancreatic Cancer (June 2, 2019): Phase III – POLO
49 Figure 7: Abraxane for Pancreatic Cancer (March 12, 2019): Phase III – APACT – w/Gemcitabine (Adjuvant)
51 Figure 8: Lynparza for Pancreatic Cancer (February 26, 2019): Phase III – POLO
53 Figure 9: SM-88 for Pancreatic Cancer (January 18, 2019): Phase II – Tyme-88-Panc (>1L)
55 Figure 10: BL-8040 for Pancreatic Cancer (October 19, 2018): Phase IIa – COMBAT/KEYNOTE-202 (w/Keytruda)
57 Figure 11: AM0010 for Pancreatic Cancer (June 3, 2018): Phase I/Ib – 001
58 Figure 12: Key upcoming events in pancreatic cancer
59 Figure 13: Probability of success in the pancreatic cancer pipeline
60 Figure 14: Licensing and asset acquisition deals in pancreatic cancer, 2014–19
62 Figure 15: Parent patents in pancreatic cancer, 2019–25
63 Figure 16: Parent patents in pancreatic cancer, 2025–29
63 Figure 17: Parent patents in pancreatic cancer, 2029–38
66 Figure 18: Clinical trials in pancreatic cancer
66 Figure 19: Top 10 drugs for clinical trials in pancreatic cancer
67 Figure 20: Top 10 companies for clinical trials in pancreatic cancer
67 Figure 21: Trial locations in pancreatic cancer
68 Figure 22: Pancreatic cancer trials status
69 Figure 23: Pancreatic cancer trials sponsors, by phase
LIST OF TABLES
14 Table 1: Incident cases of pancreatic cancer, 2017–26
17 Table 2: Marketed drugs for pancreatic cancer
21 Table 3: Pipeline drugs for pancreatic cancer in the US
40 Table 4: Mavorixafor for Pancreatic Cancer (July 17, 2019)
41 Table 5: Napabucasin for Pancreatic Cancer (July 1, 2019)
42 Table 6: Abraxane for Pancreatic Cancer (June 2, 2019)
43 Table 7: Lynparza for Pancreatic Cancer (June 2, 2019)
45 Table 8: MVT-5873 for Pancreatic Cancer (May 8, 2019)
46 Table 9: Sacituzumab Govitecan for Pancreatic Cancer (April 29, 2019)
47 Table 10: RX-3117 for Pancreatic Cancer (April 16, 2019)
48 Table 11: Abraxane for Pancreatic Cancer (March 12, 2019)
49 Table 12: Abraxane for Pancreatic Cancer (February 27, 2019)
50 Table 13: Lynparza for Pancreatic Cancer (February 26, 2019)
52 Table 14: SM-88 for Pancreatic Cancer (January 18, 2019)
54 Table 15: BL-8040 for Pancreatic Cancer (October 19, 2018)
55 Table 16: AM0010 for Pancreatic Cancer (June 3, 2018)
64 Table 17: Historical global sales, by drug ($m), 2014–18
65 Table 18: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the